Colorectal cancer cells do not simply burn fuel faster than healthy cells — a review published this week in Genes & Diseases argues they rewire how they use glucose, fat and amino acids to grow, dodge immune attack and resist chemotherapy.
The work, led by Wen Xiao, Dan Tan and Wen Zeng of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, with colleagues at Ganzhou Cancer Hospital, Gannan Medical University, reframes metabolism as a driver of tumor behavior, not just its power supply.
That distinction matters. For decades, the working assumption was that altered metabolism in cancer was a consequence of rapid growth — a cell burning sugar badly because it was dividing quickly. The review, covered by News-Medical and EurekAlert!, argues the opposite direction of causation: the metabolic rewiring helps determine whether a tumor survives, spreads to the liver and responds to treatment.
It also explains a familiar clinical frustration. Drugs that block a single metabolic pathway have produced inconsistent results across colorectal tumors, and the authors attribute this to what they call metabolic flexibility — some cancer cells fall back on mitochondrial energy production even when glucose fermentation is shut down.
The writers flag their own limits, too. Metabolic needs differ by tumor stage and cell type, many proposed interventions lack clinical validation, and the biggest evidence gaps involve cancer stem cells and microsatellite-stable colorectal cancer — the form that accounts for most cases.
Cancer Cells Switch Energy Pathways
- Cancer cells in the colon can switch between two ways of making energy, which is why single-target metabolic drugs have struggled.
- Lactate — often dismissed as waste — appears to help tumors resist chemotherapy and suppress nearby immune cells.
- Nothing in this review changes current patient care yet; it maps targets that still need testing in clinical trials.
Colorectal Tumors Use Dual Energy Systems
The best-known metabolic signature in cancer is the Warburg effect: cells convert glucose into lactate even when oxygen is plentiful — a process called aerobic glycolysis. In plain terms, the tumor runs an inefficient fuel system on purpose, because the same pipeline also manufactures the molecular building blocks — nucleotides, lipids, amino acids — needed to build new cells.
But colorectal tumors, the review finds, do not rely on this exclusively. Some cells keep using their mitochondria, the cell’s standard power plants. This dual capability is the review’s explanation for why blocking one pathway may help one tumor and leave another untouched.
Lactate receives particular attention. Beyond its role as a byproduct, the authors describe it as fuel for neighboring cells and as a modifier of the tumor microenvironment — the surrounding mix of immune and supporting cells. Changes in how lactate is produced and transported are linked to chemotherapy resistance and immune suppression, which makes lactate transporters a candidate target for drug combinations.
Fat, Glutamine and the Nutrient Contest
The review extends the picture beyond sugar. Altered fat metabolism and dependence on amino acids — notably glutamine — sustain cancer cells, and these pathways interact with the signaling machinery that controls cell survival. Exploiting those dependencies, the authors argue, could weaken tumors or restore sensitivity to existing medicines.
Metabolism is also a contest. Immune cells and stromal cells inside the tumor compete for the same nutrients and trade metabolites with cancer cells. According to the review, losing that contest undermines immune responses and helps the cancer establish itself in distant organs, including the liver — the most common site of colorectal metastasis.
Where This Could Reach Patients
Two applications emerge. First, metabolic biomarkers — measurable metabolic signatures in blood or tissue — could improve early diagnosis and help match treatments to a tumor’s metabolic profile. Second, metabolic interventions could be layered onto chemotherapy, targeted therapies or immunotherapy, an approach the authors present as the most realistic route to the clinic.
For patients in the United States, United Kingdom and Europe, the practical impact today is nil: no metabolic-targeting regimen for colorectal cancer has cleared review by the FDA, EMA or NHS regulators on the strength of this work.
The review’s relevance to those systems is its research agenda — it tells drug developers and trial designers which dependencies to test, particularly in microsatellite-stable disease, where immunotherapy benefits only a small minority of patients.
Review Synthesizes Mechanistic Research Only
The review is a synthesis of mechanistic research, not a clinical trial, so it reports no efficacy figures, survival rates or sample sizes. The comparable findings it organizes are qualitative:
| Metabolic pathway | Role in tumor | Clinical implication per the review |
|---|---|---|
| Aerobic glycolysis (Warburg effect) | Converts glucose to lactate; supplies building blocks for growth | Single-pathway blockers give inconsistent results due to metabolic flexibility |
| Lactate production and transport | Fuel source; modifies tumor microenvironment | Linked to chemotherapy resistance and immune suppression; candidate drug target |
| Lipid metabolism | Sustains cell membranes and signaling | Potential vulnerability when combined with existing therapies |
| Glutamine and amino acid dependence | Feeds cell-survival machinery | Targetable dependency; validation still pending |
On funding, neither News-Medical nor the EurekAlert! release discloses the financial support behind the review, and the article text available does not state it. That is a transparency gap readers should weigh — the journal, Genes & Diseases, describes itself as publishing peer-reviewed work on the molecular bases of human disease.
No metabolic diet, supplement or drug regimen is supported by this review for patients or the general public, and the authors themselves state that most proposed approaches still require clinical validation.
What remains unchanged is standard guidance: colorectal cancer screening saves lives, and anyone with symptoms — rectal bleeding, a persistent change in bowel habits, unexplained weight loss or iron-deficiency anemia — should consult a physician promptly. Patients already in treatment should raise questions about metabolic therapies with their oncologist rather than acting on early-stage laboratory findings.
The Trajectory From Here
The honest reading of this review is that colorectal cancer’s metabolism is a map, not a medicine. Its authors identify where interventions might work and where the evidence is thinnest — cancer stem cells and the microsatellite-stable majority. Until those hypotheses survive controlled trials, the review’s most immediate value is diagnostic: metabolic biomarkers, if validated, could move detection earlier than any metabolic drug now can.
References
- Xiao, W., Tan, D., Zeng, W., Nie, X., Wang, M. (2026). Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights. Genes & Diseases. DOI: 10.1016/j.gendis.2026.102054
- News-Medical: Colorectal cancer rewires metabolism to fuel growth and resist treatment
- EurekAlert!: Colorectal cancer’s metabolic adaptations reveal potential treatment targets
Consult a qualified healthcare professional regarding any diagnosis or treatment.